Articles tagged "Immunogenicity"

2021 American Transplant Congress
Tissue Specific Antigen-presentation in VCA Transplantation
B. Kern¹, J. Mengwasser¹, A. Reutzel-Selke¹, M. I. Ashraf¹, D. Polenz¹, K. Fuehrer¹, S. Lippert¹, P. Tang¹, F. Martin¹, C. Witzel¹, I. M. Sauer¹, J. Pratschke¹, S. G. Tullius²
¹Dept. of Surgery, Charité Campus CCM|CVK, Universitaetsmedizin Berlin, Germany, Berlin, Germany, ²Division of Transplant Surgery and Transplant Surgery Research Laboratory, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
*Purpose: Vascular Composite Tissue Allotransplantation (VCA) has become a clinical reality. High frequencies of acute rejections remain an unsolved problem. Here, we delineated components of…
2021 American Transplant Congress
Hla-dq Epitope Mismatch Predicts De Novo Donor-Specific Antibody Formation and Acute Cellular Rejection After Living Donor Liver Transplantation
K. Ono, K. Ide, Y. Tanaka, M. Ohira, H. Tahara, N. Tanimine, S. Akimoto, Y. Imaoka, K. Sato, H. Yamane, N. Tsukiyama, R. Ide, T. Mochizuki, H. Ohdan
Department of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health S, Hiroshima University, Hiroshima City, Japan
*Purpose: Epitope mismatch (MM) effect on living donor liver transplantation (LDLT) has not been studied in detail. This study aimed to investigate the role of…
2021 American Transplant Congress
Precision Medicine in Renal Transplantation: T-cell Repertoire Sequencing to Define Donor-specific Clones for Post-transplant Monitoring
K. R. Sherwood¹, P. Wong¹, F. Fenninger¹, V. Wu¹, J. Beckrud², D. P. Cina³, L. Allan², J. Lan², P. A. Keown²
¹University of British Columbia, Vancouver, BC, Canada, ²Vancouver General Hospital, Vancouver, BC, Canada, ³Urologic Sciences, Vancouver General Hospital, Vancouver, BC, Canada
*Purpose: Measuring donor-specific clonal responses offers a precise, sensitive and specific biomarker of immune recognition and activation. Combining deep immunophenotyping (DI) and T-cell receptor (TCR)…
2021 American Transplant Congress
Clearance of Viral RNA and DNA and Antibody Response Following Administration of Live Attenuated Measles and Varicella Vaccines in Children with Chronic Liver Disease
S. Kemme¹, A. Weinberg², A. G. Feldman¹
¹Children's Hospital Colorado, Denver, CO, ²University of Colorado Denver, Denver, CO
*Purpose: Guidelines recommend waiting four weeks between live vaccine administration and transplantation; however, there is little data to support this waiting period and it often…
2020 American Transplant Congress
Molecular Features of HLA Mismatches as Predictors of De Novo DSA Development: A Single Center Experience
V. Jucaud¹, L. Rebellato², K. Briley², C. Haisch², S. Kendrick³, H. Jones³, K. Mclawhorn³, D. Leeser², M. Everly¹
¹Terasaki Research Institute, Los Angeles, CA, ²East Carolina University, Greenville, NC, ³Eastern Nephrology Associates, Greenville, NC
*Purpose: Several molecular features (MoFs) of HLA mismatches (MMs) are currently used to predict the development of de novo donor-specific anti-HLA antibodies (dnDSA). The purpose…
2020 American Transplant Congress
HLA Mismatch Immunogenicity: Are We Predicating Mismatches That Induce De Novo DSA Development or That Do Not?
V. Jucaud¹, L. Rebellato², K. Briley², C. Haisch², S. Kendrick³, H. Jones³, K. Mclawhorn³, D. Leeser², M. Everly¹
¹Terasaki Research Institute, Los Angeles, CA, ²East Carolina University, Greenville, NC, ³Eastern Nephrology Associates, Greenville, NC
*Purpose: Although the development of de novo donor-specific anti-HLA antibodies (dnDSA) remains a major risk factor for poor long-term kidney allograft outcomes, the prediction of…
2020 American Transplant Congress
The Impact of HLA-DQ Molecular Mismatches on De Novo Occurrence of Donor-Specific Anti-HLA Antibodies after Kidney Transplantation: An Observational Cohort Study
A. Senev¹, M. Coemans¹, V. Van Sandt², E. Van Loon¹, J. Callemeyn¹, B. Sprangers¹, D. Kuypers¹, M. Emonds¹, M. Naesens¹
¹Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium, ²HILA, Red Cross-Flanders, Mechelen, Belgium
*Purpose: Evaluating HLA molecular mismatches (MM) instead of antigen mismatches might be a better tool to assess donor-recipient HLA incompatibility and provide a better risk…
2020 American Transplant Congress
Relapse-Prone Unresectable Hepatoblastoma (HB) Requiring Liver Transplantation (LT) Are Immunogenic and May Be Sensitive to Immune Checkpoint Inhibitors
M. Ningappa¹, C. Ashokkumar¹, J. Garifallou², M. Gonzalez², H. Hakonarson², S. Ranganathan¹, B. W. Higgs¹, R. Sindhi¹
¹Pediatric Transplant, Pittsburgh, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA
*Purpose: Unresectable HB accounts for 8% of all pediatric LT. Post-LT relapse rates approach 20% indicating a need for more effective neoadjuvant chemotherapy.*Methods: To discover…
2020 American Transplant Congress
A Simple HLA Class II Matching Strategy for the Prediction of De Novo Donor-Specific HLA Antibodies
L. G. Hidalgo¹, I. A. Martinez Juarez², L. Morales-Buenrostro³, S. Shojai⁴, P. Campbell⁴
¹Surgery, University of Wisconsin - Madison, Madison, WI, ²Nephrology, Hospital Angeles Pedregal, Mexico City, Mexico, ³Nephrology, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, ⁴Medicine, University of Alberta, Edmonton, AB, Canada
*Purpose: In kidney transplantation, degree of HLA Class II mismatch (MM) between donor and recipient drives the risk to develop de novo DSA (dnDSA). New…
2020 American Transplant Congress
Immunomodulation During Normothermic Ex Vivo Machine Perfusion of the Rat Liver
K. Carlson¹, F. Najmabadi¹, J. Pavan-Guimaraes¹, W. J. Burlingham¹, C. M. Capitini², D. P. Al-Adra¹
¹Surgery, University of Wisconsin, Madison, WI, ²Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, WI
*Purpose: Transplantation is the best treatment option for end-stage liver failure. There remains a critical need to develop targeted therapeutic strategies to decrease graft rejection…